Literature DB >> 21325464

Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction.

Paulina Pettinelli1, Luis A Videla.   

Abstract

INTRODUCTION: Triglyceride accumulation in the liver is an early feature in the development of nonalcoholic fatty liver disease (NAFLD) associated with human obesity, which is a multifactorial syndrome and whose underlying mechanisms are beginning to be understood.
OBJECTIVES: Liver peroxisome proliferator-activated receptor-γ (PPAR-γ) mRNA expression was measured as a signaling mechanism related to steatosis in obese patients with NAFLD.
METHODS: Liver PPAR-γ and sterol receptor element-binding protein 1c (SREBP-1c) mRNA (real-time RT-PCR), serum total adiponectin (RIA), and high molecular weight (HMW)-adiponectin (ELISA) levels, and insulin resistance (IR) evolution (homeostasis model assessment-IR) were determined in 22 obese NAFLD patients (16 with steatosis and six with steatohepatitis) who underwent subtotal gastrectomy with gastrojejunal anastomosis in Roux-en-Y and 16 nonobese subjects who underwent laparoscopic cholecystectomy (controls).
RESULTS: Liver PPAR-γ mRNA levels were 112 and 188% higher (P < 0.05) than control values in obese patients with steatosis and steatohepatitis, respectively, who also exhibited 70 and 62% increases in those of SREBP-1c, concomitantly with IR and lower levels of serum total adiponectin and HMW-adiponectin (P < 0.05). Liver PPAR-γ expression showed positive associations with SREBP-1c mRNA levels (r = 0.86; P < 0.0001), serum insulin levels (r = 0.39; P < 0.01), and homeostasis model assessment-IR (r = 0.60; P < 0.0001), and negative correlations with total adiponectin (r = -0.37; P < 0.01) and HMW-adiponectin (r = -0.51; P < 0.001) levels in serum.
CONCLUSIONS: PPAR-γ is up-regulated in the liver of obese patients with NAFLD, representing an additional reinforcing lipogenic mechanism to SREBP-1c induction in the development of hepatic steatosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325464     DOI: 10.1210/jc.2010-2129

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  98 in total

1.  High dietary intake of palm oils compromises glucose tolerance whereas high dietary intake of olive oil compromises liver lipid metabolism and integrity.

Authors:  Youzan Ferdinand Djohan; Eric Badia; Beatrice Bonafos; Gilles Fouret; Céline Lauret; Anne-Marie Dupuy; Edith Pinot; Thibault Sutra; Sylvie Gaillet; Karen Lambert; Fabrice Raynaud; Nathalie Gayrard; Bernard Jover; Absalome Aké Monde; Jean Paul Cristol; Charles Coudray; Christine Feillet-Coudray
Journal:  Eur J Nutr       Date:  2018-11-03       Impact factor: 5.614

2.  Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents.

Authors:  Hui Chen; David Simar; Katherine Pegg; Sonia Saad; Clovis Palmer; Margaret J Morris
Journal:  Diabetologia       Date:  2013-12-14       Impact factor: 10.122

3.  High protein/fish oil diet prevents hepatic steatosis in NONcNZO10 mice; association with diet/genetics-regulated micro-RNAs.

Authors:  Nikhil Adi; Jennipher Adi; Roberta Marques Lassance-Soares; Paul Kurlansky; Hong Yu; Keith A Webster
Journal:  J Diabetes Metab       Date:  2016-06-16

4.  Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease.

Authors:  Vanessa Souza-Mello
Journal:  World J Hepatol       Date:  2015-05-18

5.  Inhibition of hepatocyte nuclear factor 1b induces hepatic steatosis through DPP4/NOX1-mediated regulation of superoxide.

Authors:  Zi Long; Meng Cao; Shuhao Su; Guangyuan Wu; Fansen Meng; Hao Wu; Jiangzheng Liu; Weihua Yu; Kamran Atabai; Xin Wang
Journal:  Free Radic Biol Med       Date:  2017-09-21       Impact factor: 7.376

6.  Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice.

Authors:  Abigail Wolf Greenstein; Neena Majumdar; Peng Yang; Papasani V Subbaiah; Rhonda D Kineman; Jose Cordoba-Chacon
Journal:  J Endocrinol       Date:  2016-10-31       Impact factor: 4.286

7.  A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes.

Authors:  Md Abdul Hye Khan; Lauren Kolb; Melissa Skibba; Markus Hartmann; René Blöcher; Ewgenij Proschak; John D Imig
Journal:  Diabetologia       Date:  2018-07-21       Impact factor: 10.122

8.  FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver.

Authors:  Dae Hyun Kim; Ting Zhang; Sojin Lee; Virtu Calabuig-Navarro; Jun Yamauchi; Ann Piccirillo; Yong Fan; Radha Uppala; Eric Goetzman; H Henry Dong
Journal:  Endocrinology       Date:  2014-01-17       Impact factor: 4.736

9.  Semantic MEDLINE for discovery browsing: using semantic predications and the literature-based discovery paradigm to elucidate a mechanism for the obesity paradox.

Authors:  Michael J Cairelli; Christopher M Miller; Marcelo Fiszman; T Elizabeth Workman; Thomas C Rindflesch
Journal:  AMIA Annu Symp Proc       Date:  2013-11-16

10.  Hepatic PPARγ Is Not Essential for the Rapid Development of Steatosis After Loss of Hepatic GH Signaling, in Adult Male Mice.

Authors:  Rhonda D Kineman; Neena Majumdar; Papasani V Subbaiah; Jose Cordoba-Chacon
Journal:  Endocrinology       Date:  2016-03-07       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.